Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

ClinicalTrials.gov ID: NCT02962414

Public ClinicalTrials.gov record NCT02962414. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304.

Study identification

NCT ID
NCT02962414
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
206 participants

Conditions and interventions

Interventions

  • everolimus Drug

Drug

Eligibility (public fields only)

Age range
2 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 7, 2017
Primary completion
Aug 3, 2027
Completion
Aug 12, 2027
Last update posted
Apr 1, 2026

2017 – 2027

United States locations

U.S. sites
14
U.S. states
11
U.S. cities
14
Facility City State ZIP Site status
TGen APNNA Phoenix Arizona 85012
David Geffen School of Medicine at UCLA Los Angeles California 90005-1752
UCSF Benioff Children s Hospital Oakland California 94609
Rady Children s Hospital San Diego California 92123
University of Colorado School of Medicine Aurora Colorado 80045
Connecticut Childrens Medical Cntr Hartford Connecticut 06106
University of Chicago Medical Center Chicago Illinois 60637
Minnesota Epilepsy Group Saint Paul Minnesota 55102
Atlantic Health Systems Morristown New Jersey 07962
Cinn Children Hosp Medical Center Cincinnati Ohio 45229-3039
Oregon Health Sciences University Portland Oregon 97239
Childrens Hospital of Philadelphia Philadelphia Pennsylvania 19104
Texas Scottish Rite Hos for Child Dallas Texas 75219
Texas Childrens Hospital Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 54 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02962414, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 1, 2026 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02962414 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →